FDA Issues Prescription Labeling Draft Guidance

The draft guidance will help ensure the information in product labeling on abuse, misuse, addiction, physical dependence and tolerance is clear, concise, useful, and informative.

The U.S. Food & Drug Administration has issued new draft guidance on labeling for prescription medicines. Titled "Drug Abuse and Dependence Section of Labeling for Human Prescription Drug and Biological Products - Content and Format," the draft contains recommendations that represent FDA's current thinking on the content and format of this section for prescription medications that are scheduled under the Controlled Substances Act, as well as for prescription medications not scheduled under the CSA for which there is important information to convey to health care professionals related to abuse and dependence.

"Our goal is that this guidance will help ensure that information in product labeling on abuse, misuse, addiction, physical dependence and tolerance is clear, concise, useful and informative," the agency's news release states. For example, the draft guidance recommends that terminology used in the Drug Abuse and Dependence section – such as abuse, misuse, addiction, physical dependence, and tolerance – be defined in labeling to ensure common understanding, and FDA has included recommended definitions. The guidance says that a person who takes a friend's prescription opioid medication to relieve tooth pain is misusing the medication; if that person takes a friend's opioid to get a euphoric high, that use represents abuse of the medication.

A second draft guidance announced July 1, "Instructions for Use — Patient Labeling for Human Prescription Drug and Biological Products and Drug-Device and Biologic-Device Combination Products — Content and Format," relates to how the drug or biologic is used. Instructions for Use (IFU) is a type of labeling for patients who use products that have complicated or detailed patient-use instructions; it offers detailed, action-oriented, step-by-step written and visual instructions in a patient-friendly manner and typically includes instructions on preparation, administration, handling, storage, and disposal.

The recommendations in the IFU guidance are intended to promote development of consistent content and format across IFUs.

Download Center

HTML - No Current Item Deck
  • Get the Ultimate Guide to OSHA Recordkeeping

    OSHA’s Form 300A posting deadline is February 1! Are you prepared? To help answer your key recordkeeping questions, IndustrySafe put together this guide with critical compliance information.

  • Steps to Conduct a JSA

    We've put together a comprehensive step-by-step guide to help you perform a job safety analysis (JSA), which includes a pre-built, JSA checklist and template, steps of a JSA, list of potential job hazards, and an overview of hazard control hierarchy.

  • Everything You Need to Know about Incident investigations

    Need some tips for conducting an incident investigation at work after there’s been an occupational injury or illness, or maybe even a near miss? This guide presents a comprehensive overview of methods of performing incident investigations to lead you through your next steps.

  • Free Safety Management Software Demo

    IndustrySafe Safety Management Software helps organizations to improve safety by providing a comprehensive toolset of software modules to help businesses identify trouble spots; reduce claims, lost days, OSHA fines; and more.

  • Industry Safe

OH&S Digital Edition

  • OHS Magazine Digital Edition - November December 2020

    November December 2020

    Featuring:

    • COLD STRESS
      Managing Cold Stress
    • TRAINING: FALL PROTECTION
      Providing Training for Fall Protection
    • PPE: HEARING PROTECTION
      Eight Tips for Hearing Testing Day
    • FACILITY SECURITY
      Incorporating COVID-19 Protections into Safety Programs
    View This Issue